Who is sponsoring NCT05782426?

NCT05782426 is sponsored by Jiangsu Cancer Institute & Hospital.

What drugs are being tested in NCT05782426?

Interventions in NCT05782426: paclitaxel polymeric micelles for injection.

What condition does NCT05782426 study?

NCT05782426 studies Non-squamous NSCLC.

Is NCT05782426 still recruiting?

NCT05782426 is currently status unknown. Last updated 23 March 2023.

Last reviewed 2023-03-23 · How we verify

NCT05782426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC

Status unknown Phase 2 Last updated 23 March 2023

What this trial tests

Phase 2 trial testing paclitaxel polymeric micelles for injection in Non-squamous NSCLC in 28 participants. Status unknown.

Timeline

15 March 2023

Primary endpoint
31 January 2024

31 January 2026

Quick facts

Lead sponsor	Jiangsu Cancer Institute & Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	15 March 2023
Primary completion	31 January 2024
Estimated completion	31 January 2026
Sites	2 locations across China

Drugs / interventions tested

paclitaxel polymeric micelles for injection — full drug profile →

Conditions studied

Non-squamous NSCLC — all drugs for Non-squamous NSCLC →

Sponsor

Jiangsu Cancer Institute & Hospital

Who can join

18 and older, any sex, with Non-squamous NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm, single-center, phaseⅡtrial to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection, platinum (cisplatin/carboplatin) in combination with sindilizumab injection as first-line chemotherapy in advanced or metastatic non-squamous NSCLC patients without EGFR mutation or ALK rearrangement.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials.
Serras A, Faustino C, Pinheiro L. · · 2024 · cited 4× · PMID 39204392 · DOI 10.3390/pharmaceutics16081047

Verify or expand the search:

Other trials of paclitaxel polymeric micelles for injection

Trials testing the same drug.

NCT06752811 — Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer · Phase 3 · recruiting

Other recruiting trials for Non-squamous NSCLC

Currently open trials in the same condition.

NCT05751187 — Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients · Phase 2 · active not recruiting
NCT04413201 — AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T7 · Phase 4 · active not recruiting

Other Jiangsu Cancer Institute & Hospital trials

Trials by the same sponsor.

NCT07408609 — Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal · Phase 2 · not yet recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT07446387 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regim · Phase 2 · not yet recruiting
NCT07311577 — Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD- · Phase 2 · recruiting
NCT05912582 — Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05782426 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Cancer Institute & Hospital
Last refreshed: 23 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05782426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing